Tirzepatide (Research Use Only)

Chemical Name: Tirzepatide

CAS Number:
2023788-19-2

Molecular Weight: 4810.52–4813.5 g/mol

Sequence:
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{C20 diacid-gamma-Glu-(AEEA)₂-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
(reference)

Appearance: White to off-white powder

Storage: −20°C (long-term)

Form: Lyophilized solid; soluble in DMSO

Description

Tirzepatide is a 39-amino acid synthetic polypeptide and dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is widely researched for glycemic control and significant weight-loss effects in metabolic and obesity models. It utilizes albumin affinity modifications (C20 fatty diacid sidechain) for extended half-life and once-weekly use in studies.
(Wikipedia)
(DrugBank)

Research Applications

Studies on glycemic regulation in metabolic disease and T2DM models
Obesity research: Significant dose-dependent weight reduction (clinical and preclinical)
Investigated effects on fasting insulin, HbA1c, cardiovascular risk factors
Used in high-impact trials for diabetes and obesity

Key Research & Reports

Mechanism of Action

Tirzepatide binds to both GIP and GLP-1 receptors, stimulating insulin secretion, inhibiting glucagon, and slowing gastric emptying. This dual incretin agonism leads to improved glucose control and substantial weight loss in research models—distinct from single-incretin peptides.
(DrugBank)

Safety and Handling

Tirzepatide demonstrates strong safety in controlled laboratory research. Store lyophilized powder at −20°C; reconstitute prior to in vitro or in vivo studies. Known mild effects include gastrointestinal symptoms and transient injection reactions in model organisms.

Disclaimer

For laboratory research use only. Not for human consumption, medical, veterinary, or diagnostic use. All data provided is for educational and research purposes.